<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00680095</url>
  </required_header>
  <id_info>
    <org_study_id>AN2690-ONYC-101</org_study_id>
    <secondary_id>C3371011</secondary_id>
    <nct_id>NCT00680095</nct_id>
  </id_info>
  <brief_title>Cumulative Irritation Test</brief_title>
  <official_title>21-day Cumulative Irritation Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the cumulative irritation potential of the products
      listed by the Sponsor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy, adult volunteers of either sex will be patched on his/her back with AN2690 Solution
      2.5%, AN2690 Solution 5%, AN2690 Solution 7.5%, AN2690 Solution Vehicle and Sodium Laurel
      Sulfate 0.5% over the course of 21 consecutive days. After 24 hours, the patches are to be
      removed and the site evaluated using a five-point scale for irritation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2007</start_date>
  <completion_date type="Actual">February 28, 2007</completion_date>
  <primary_completion_date type="Actual">February 28, 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severe irritation (Grade 3 or 4) observed at any site</measure>
    <time_frame>Daily for 21 days</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AN2690 Solution, 2.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AN2690 Solution, 7.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AN2690 Solution, 5.0%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AN2690 Solution, Vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium Lauryl Sulfate, 0.5%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AN2690</intervention_name>
    <description>AN2690 Solution, 2.5%, Daily for up to 21 days</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AN2690</intervention_name>
    <description>AN2690 Solution, 7.5%, Daily for up to 21 days</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AN2690</intervention_name>
    <description>AN2690 Solution, 5.0%, Daily for up to 21 days</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AN2690 Solution, Vehicle</intervention_name>
    <description>AN2690 Solution, Vehicle, Daily for up to 21 days</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sodium Lauryl Sulfate, 0.5%</intervention_name>
    <description>Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days</description>
    <arm_group_label>E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, volunteers of either sex, at least 18 years of age or older

          -  Females of childbearing potential submitted to a urine pregnancy test and had negative
             results at Day 1 and at the final visit and also was using an effective method of
             birth control (e.g. abstinence, implants, injectables, oral contraceptives,
             intrauterine contraceptive devices or double barrier) or agreed to use an effective
             method of birth control prior to becoming sexual active

          -  Subjects were of any skin type or race providing their degree of pigmentation did not
             interfere with making readings of skin reactions

          -  Subjects were willing to follow the study procedures and complete the study

          -  Written informed consent was obtained

        Exclusion Criteria:

          -  Subject with any skin disease that would have in any way confounded interpretation of
             the study results. Atopic dermatitis/eczema, psoriasis or chronic asthma were excluded

          -  Subject was pregnant or nursing

          -  Subject had a history of sensitivity to any component of any of the formulations

          -  Use of chronic medications (such as antihistamines, corticosteroids, analgesics and
             anti-inflammatories) for one week before and during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Education and Research Foundation, Inc.</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2008</study_first_submitted>
  <study_first_submitted_qc>May 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2008</study_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Onychomycosis</keyword>
  <keyword>Fungal Nail</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Tavaborole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

